NewAmsterdam Pharma (NAMS) stock: insider trades, news & valuation
Health Care · Net selling
Close · Oct 9, 2026
$21.57
+1.5% on the day
-34.6% over 12 months
52-week range $21.16 – $41.45
Share price and insider trades
NAMS closeInsider buyInsider sale
Bought, 12 months$226K
Sold, 12 months$63.3M
Insiders buying1
Insiders selling6
NewAmsterdam Pharma insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $226K and 6 sold $63.3M of NAMS stock on the open market.
Get emailed when insiders cluster-buy stocks like NAMS
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
NAMS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $226K | 1 | $7.8M | 6 |
| Q2 2026 | — | 0 | $3.5M | 3 |
| Q1 2026 | — | 0 | $46.7M | 30 |
| Q4 2025 | — | 0 | $5.2M | 3 |
Valuation, profit and volume
Pick score 44/100P/E (trailing)n/aSector median 24.7
Market value$2.52BBiotechnology
Profit margin0.0%Revenue growth -80.7%
Volume vs. 50-day0.9×Last 5 sessions
Insiders' paper profit−$11KOn all tracked purchases -4.7%
Summary
Over the past 12 months, 1 NewAmsterdam Pharma Co N.V. insider reported open-market purchases totaling $226K, while 6 insiders reported sales totaling $63.3M. 36 of 43 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
NAMS stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 2SEC | Johannes Jacob Pieter KasteleinChief Scientific Officer | Sell Plan | 50,24669,302 held (−42%) | $25.03 | $1.3M | -13.8% | — |
| Sep 15SEC | Michael H. DavidsonCEO | Buy | 10,000792,923 held (+1%) | $22.65 | $226K | -4.7% | — |
| Sep 9SEC | John W SmitherDirector | Sell | 1,6008,760 held (−15%) | $25.32 | $41K | -14.8% | — |
| Aug 25SEC | Johannes Jacob Pieter KasteleinChief Scientific Officer | Sell Plan | 125,00069,302 held (−64%) | $26.91 | $3.4M | -19.8% | — |
| Jul 22SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 70,20059,153 held (−54%) | $29.96 | $2.1M | -28.0% | — |
| Jul 22SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 31,88527,268 held (−54%) | $31.05 | $990K | -30.5% | — |
| Jul 22SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 2,91524,353 held (−11%) | $31.71 | $92K | -32.0% | — |
| Jun 24SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 39,70024,653 held (−62%) | $30.20 | $1.2M | -28.6% | — |
| Jun 24SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 30024,353 held (−1%) | $30.73 | $9K | -29.8% | — |
| May 27SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 65,00024,353 held (−73%) | $35.69 | $2.3M | -39.5% | — |
| Mar 12SEC | Louis G LangeDirector | Sell | 44,17310,806 held (−80%) | $30.41 | $1.3M | -29.1% | — |
| Mar 12SEC | Louis G LangeDirector | Sell | 44610,360 held (−4%) | $31.23 | $14K | -30.9% | — |
| Mar 10SEC | Louis G LangeDirector | Sell | 28,186 | $29.41 | $829K | -26.6% | — |
| Mar 9SEC | Johannes Jacob Pieter KasteleinChief Scientific Officer | Sell Plan | 104,46769,302 held (−60%) | $30.30 | $3.2M | -28.8% | — |
| Mar 9SEC | Johannes Jacob Pieter KasteleinChief Scientific Officer | Sell Plan | 101,40969,302 held (−59%) | $30.29 | $3.1M | -28.8% | — |
| Mar 9SEC | Johannes Jacob Pieter KasteleinChief Scientific Officer | Sell Plan | 94,12469,302 held (−58%) | $30.32 | $2.9M | -28.8% | — |
| Mar 2SEC | Michael H. DavidsonCEO | Sell | 443,707174,144 held (−72%) | $33.25 | $14.8M | -35.1% | — |
| Feb 26SEC | Michael H. DavidsonCEO | Sell Plan | 165,408477,783 held (−26%) | $33.63 | $5.6M | -35.8% | — |
| Feb 26SEC | Michael H. DavidsonCEO | Sell Plan | 61,547463,020 held (−12%) | $36.13 | $2.2M | -40.3% | — |
| Feb 26SEC | Michael H. DavidsonCEO | Sell Plan | 46,517471,595 held (−9%) | $35.11 | $1.6M | -38.6% | — |
| Feb 26SEC | Michael H. DavidsonCEO | Sell Plan | 17,924174,144 held (−9%) | $34.44 | $617K | -37.4% | — |
| Feb 26SEC | Michael H. DavidsonCEO | Sell Plan | 10,436461,159 held (−2%) | $35.96 | $375K | -40.0% | — |
| Feb 26SEC | Michael H. DavidsonCEO | Sell Plan | 3,161459,859 held (−1%) | $36.46 | $115K | -40.8% | — |
| Feb 26SEC | Michael H. DavidsonCEO | Sell Plan | 1,300459,859 held (−0%) | $36.68 | $48K | -41.2% | — |
| Feb 24SEC | Johannes Jacob Pieter KasteleinChief Scientific Officer | Sell | 30,78953,500 held (−37%) | $35.46 | $1.1M | -39.2% | — |
| Feb 24SEC | Johannes Jacob Pieter KasteleinChief Scientific Officer | Sell | 14,69284,289 held (−15%) | $35.00 | $514K | -38.4% | — |
| Jan 29SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 39,81624,353 held (−62%) | $32.62 | $1.3M | -33.9% | — |
| Jan 29SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 32,61224,353 held (−57%) | $31.80 | $1.0M | -32.2% | — |
| Jan 27SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 34,09124,662 held (−58%) | $32.77 | $1.1M | -34.2% | — |
| Jan 27SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 25,40537,120 held (−41%) | $33.44 | $850K | -35.5% | — |
| Jan 27SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 12,76724,353 held (−34%) | $34.37 | $439K | -37.2% | — |
| Jan 27SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 30924,353 held (−1%) | $33.45 | $10K | -35.5% | — |
| Jan 22SEC | Mayur Ian SomaiyaCFO | Sell Plan | 39,71277,986 held (−34%) | $31.78 | $1.3M | -32.1% | — |
| Jan 22SEC | Mayur Ian SomaiyaCFO | Sell Plan | 24,36258,382 held (−29%) | $33.80 | $823K | -36.2% | — |
| Jan 22SEC | Mayur Ian SomaiyaCFO | Sell Plan | 19,60458,382 held (−25%) | $32.38 | $635K | -33.4% | — |
| Jan 22SEC | Mayur Ian SomaiyaCFO | Sell Plan | 15,42282,744 held (−16%) | $33.25 | $513K | -35.1% | — |
| Jan 22SEC | Mayur Ian SomaiyaCFO | Sell Plan | 900117,698 held (−1%) | $30.64 | $28K | -29.6% | — |
| Jan 9SEC | Michael H. DavidsonCEO | Sell Plan | 11,582378,859 held (−3%) | — | $0 | — | — |
| Jan 7SEC | Johannes Jacob Pieter KasteleinChief Scientific Officer | Sell Plan | 6,00073,481 held (−8%) | $33.25 | $200K | -35.1% | — |
| Jan 7SEC | Mayur Ian SomaiyaCFO | Sell Plan | 5,11832,882 held (−13%) | $33.25 | $170K | -35.1% | — |
| Jan 7SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 2,64712,353 held (−18%) | $33.25 | $88K | -35.1% | — |
| Dec 29SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 75,11715,000 held (−83%) | $36.21 | $2.7M | -40.4% | — |
| Dec 29SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 43,87215,000 held (−75%) | $35.30 | $1.5M | -38.9% | — |
| Dec 29SEC | Louise Frederika KooijChief Accounting Officer | Sell Plan | 26,01115,000 held (−63%) | $35.68 | $928K | -39.5% | — |
Insiders at NewAmsterdam Pharma Co N.V.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Michael H. DavidsonCEO | $226K | $25.3M | Sep 15, 2026 | — |
| Louise Frederika KooijChief Accounting Officer | — | $16.8M | Jul 22, 2026 | — |
| Johannes Jacob Pieter KasteleinChief Scientific Officer | — | $15.5M | Oct 2, 2026 | — |
| Mayur Ian SomaiyaCFO | — | $3.4M | Jan 22, 2026 | — |
| Louis G LangeDirector | — | $2.2M | Mar 12, 2026 | — |
| John W SmitherDirector | — | $41K | Sep 9, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
NAMS stock: common questions
Are NewAmsterdam Pharma Co N.V. insiders buying NAMS stock?
In the past 12 months, 1 insiders reported open-market purchases of NAMS worth $226K. The latest was CEO Michael H. Davidson bought $226K of NAMS at $22.65 — first open-market purchase in our records.
Are NewAmsterdam Pharma Co N.V. insiders selling NAMS stock?
6 insiders reported sales worth $63.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is NAMS's 52-week range?
Over the past year NAMS has traded between $21.16 and $41.45. It last closed at $21.57 on Oct 9, 2026.